robots in health care

Houston-area hospital performs first robotic-assisted lung surgery

This hospital has conducted a unique and innovative procedure using robotics. Photo via hcahoustonhealthcare.com

HCA Houston Healthcare Clear Lake performed its first peripheral lung biopsy using robotic-assisted technology this month, making it the first hospital in the area to perform the minimally-invasive and innovative procedure.

Pulmonologist Dr. Alfred Maksoud performed the first two robotically-assisted procedures on March 1 and was attended by thoracic surgeon Dr. Melissa Korb and pulmonologist Dr. Maher Dahdel.

The procedures were conducted via an ultra-thin, easily maneuverable catheter that's able to navigate tight airways and pass through tight bends. A three-dimensional module of the patient's lung (created prior to surgery through a CT scan) was displayed on a computer screen to serve as a reference point for the doctors, as well as a live camera footage inside the lung.

The technology allows doctors to now reach nodules in any airway segment in the lung and extract more precise biopsies from the peripheral lung areas.

It will make the treatment easier on patients, which traditionally would require a CT scan and needle inserted into the patient's chest wall from outside of the body to reach these abnormal spots. This presented high risks of lung collapses for those with advanced lung disease.

“The technology allows us to go through the natural airways of the lung, so there is no puncturing of the lung tissue from the outside of the lining of the lung,” Maksoud said in a statement. “It is a safer way to approach lesions that are in the periphery of the lung for patients who have fairly advanced underlying lung disease.”

Additionally, this technology will support early diagnosis of lung disease when used for screenings due to its ability to reach previously unreachable areas of the lung.

“Approximately 75 percent of lung cancer cases are diagnosed in an advanced stage. Early lung cancer detection is imperative to increase the survival rate,” Todd Caliva, CEO at HCA Houston Healthcare Clear Lake, said in a statement. “We're excited to implement new innovations that allow us to enhance the level of care our patients receive.”

Houston-area hospitals have become hubs for robotic-assisted surgery in recent years.

Baylor St. Luke's has become a top cardiac robotics program since 2019. Meanwhile, others, like Houston Methodist, have developed AI technologies to simulate entire surgeries artificially with a goal of allowing surgeons to practice and plan their technique.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted